GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Purple Biotech Ltd (NAS:PPBT) » Definitions » Machinery, Furniture, Equipment

Purple Biotech (Purple Biotech) Machinery, Furniture, Equipment : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2015. Start your Free Trial

What is Purple Biotech Machinery, Furniture, Equipment?

Purple Biotech's Machinery, Furniture, Equipment for the quarter that ended in Dec. 2023 was $0.00 Mil.


Purple Biotech Machinery, Furniture, Equipment Historical Data

The historical data trend for Purple Biotech's Machinery, Furniture, Equipment can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Purple Biotech Machinery, Furniture, Equipment Chart

Purple Biotech Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Machinery, Furniture, Equipment
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Purple Biotech Quarterly Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Machinery, Furniture, Equipment Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Purple Biotech Machinery, Furniture, Equipment Calculation

Machinery, Furniture, Equipment represents those fixed assets specifically dealing with tools, equipment and office furniture.


Purple Biotech (Purple Biotech) Business Description

Industry
Traded in Other Exchanges
Address
4 Oppenheimer Street, Science Park, Rehovot, ISR, 7670104
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219 and CM24.